David W. Fry

Centre for Cancer Biology — Australia

Medicine · Health Sciences

49h-index10.4kcitations172works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(54), Quinazolinone synthesis and applications(29), Synthesis and biological activity(23), Lung Cancer Treatments and Mutations(20), Cancer therapeutics and mechanisms(20)

Publications172 total

Data from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S4 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S2 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S2 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S3 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S3 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Data from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S4 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
2023Open Access
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
UNC Libraries·2020Open Access
Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
Gastroenterology·2020· 146 citedOpen Access
Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton’s tyrosine kinase (BTK)
Bioorganic & Medicinal Chemistry Letters·2016· 8 cited
Phone app boosts independence
Learning Disability Practice·2016
Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder
The Journal of Urology·2015· 56 cited
280 Mechanisms of Tumor Targeting with Etirinotecan Pegol (NKTR-102): the Impact of Polymer Conjugation On Tumor Accumulation
European Journal of Cancer·2012
64 Novel Thymidylate Synthase Inhibitor NKT-TSI-4a Shows Improved PK Profile and Superior Efficacy Compared to Pemetrexed
European Journal of Cancer·2012
Generation and external validation of a tumor‐derived 5‐gene prognostic signature for recurrence of lymph node‐negative, invasive colorectal carcinoma
Cancer·2012· 39 citedOpen Access
887 USING ARTIFICIAL INTELLIGENCE AND MACHINE-LEARNING ALGORITHMS WITH GENE EXPRESSION PROFILING TO PREDICT SUPERFICIAL BLADDER CANCER RECURRENCE AT INITIAL PRESENTATION
The Journal of Urology·2012
External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC).
Journal of Clinical Oncology·2011· 3 cited
page 1 of 9Next →

Frequent Co-authors

James M. Nelson(13), Alexander J. Bridges(13), William A. Denny(13), H. D. Hollis Showalter(12), Alan J. Kraker(9), Hairong Zhou(9), Gordon W. Rewcastle(9), William L. Elliott(8), Wilbur R. Leopold(8), Paul R. Keller(7), Dennis J. McNamara(7), Patricia J. Harvey(6), Amy McMichael(6), Ellen M. Dobrusin(6), Patrick W. Vincent(6), R. Thomas Winters(5), Brian D. Palmer(5), Andrew M. Thompson(5), Peter L. Toogood(4), Jeff B. Smaill(4)